Carestream Molecular expands imaging agent product line

Carestream Molecular Imaging has expanded its Kodak X-Sight imaging agent family of products to include Nanosphere Conjugates labeled with Streptavidin, which provides an effective means for life science researchers to detect biotinylated probes in fluorescent molecular biology research applications.

The Streptavidin conjugates are fully biocompatible and ideal for both in vivo and in vitro applications, providing outstanding photostability and brightness, according to Carestream.

The new product will be offered in four distinct wavelengths from ultraviolet to near infrared. They provide an incredibly bright and robust platform for translating molecular imaging experiments from in vitro to in vivo applications.

“Our novel family of X-Sight Nanospheres is gaining traction among life science researchers due to its organic composition and superior performance,” said Stephanie Chiang, worldwide director of the imaging agent business at Carestream. “Streptavidin is a popular protein used by many life science and medical researchers as a secondary detection reagent, and we expect this new conjugate to provide a safe and effective means for detecting biotinylated probes in fluorescent molecular imaging applications.”

The Kodak X-Sight imaging agent family also includes Kodak X-Sight Nanospheres and Kodak X-Sight Large Stokes Shift Dyes, which are also offered in a variety of conjugated forms and are compatible with other commercially available digital imaging systems.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.